Trend of A-share and Hong Kong stock innovative drug sector this week
In the second week of February 2022, a total of 19 stocks in the innovative drug sector in mainland and Hong Kong rose, 2 stocks were flat and 26 stocks fell. Among them, the top three gainers were Kaichuang pharmaceutical-b (+ 24.56%), Xiansheng Pharmaceutical (+ 7.63%) and Geli pharmaceutical-b (+ 6.65%). The top three declines were heyu-b (- 21.81%), clover bio-b (- 15.29%) and Yunding Xinyao (- 10.39%). This week, the A-share innovative drug sector rose 0.46%, underperforming the CSI 300 index by 0.82pp, and biomedicine fell 3.77%. In the past six months, A-share innovative drugs have fallen by 6.04%, underperforming the CSI 300 index by 3.92pp, and biomedicine has fallen by 27.08%. This week, the innovative drug sector of Hong Kong stocks rose 0.49%, underperforming the Hang Seng Index by 1.36pp, and Hang Seng healthcare fell 4.8%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 15.14%, underperforming the Hang Seng Index by 3.57pp, and Hang Seng health care has fallen by 33.81%.
Progress of key innovative drugs in China
In February, three new drugs were approved for marketing in China. This week, three drugs were approved for listing in China, and three innovative drugs were approved for new indications. They are yttrium [90Y] resin microsphere injection of sirtex medical Pty Ltd, an associate of Yuanda pharmaceutical, tetravalent influenza virus splitting vaccine of Guoguang biotechnology, avonib tablets of cornerstone pharmaceutical, baileyumab for injection of GlaxoSmithKline, and a new indication of tetravalent influenza virus splitting vaccine of Hualan Biological Engineering Inc(002007) , Amlodipine and losartan potassium tablets of Korean American drugs have been approved as a new indication.
Progress of overseas key innovative drugs
In February, three new drugs were approved by FDA. No new drugs have been approved this week.
This week’s small topic – research and development progress of KRAS target drugs
There are a total of 70 research projects targeting KRAS in the world, including 1 listing, 2 phase III, 7 phase II / phase I and phase II and 13 phase I. The fastest progress is Amgen’s sotorasib, which was approved to be listed in the United States in 2021. Its indications are the second-line treatment of krasg12c mutation, unresectable, advanced and / or recurrent non-small cell lung cancer. Sotorasib phase II clinical results showed that in most patients treated with 2L, Orr was 37.1%, MPFs was 6.8 months and MOS was 12.5 months.
There are 24 KRAS projects under research in China, including 1 phase III, 4 phase I and II, and 4 phase I. others are in preclinical. Relevant listed companies in China include zaiding pharmaceutical, Cinda biology, jiakesi, Betta Pharmaceuticals Co.Ltd(300558) , Suzhou Zelgen Biopharmaceuticals Co.Ltd(688266) , Shanghai Junshi Biosciences Co.Ltd(688180) , Yasheng pharmaceutical, nuocheng Jianhua, Deqi pharmaceutical and Heyu pharmaceutical.
Progress of global key innovative drug transactions this week
There were 16 key transactions in the world this week, and 7 key transactions with disclosed amount, involving companies including obseva and theramex, akso and Huadong Medicine Co.Ltd(000963) , Biogen and xbrane, Amgen and plexium, mersana therapeutics and Johnson & Johnson, synapfix inks and macrogenetics, Brickell biotech and CARNA biosciences.
Risk warning: drug price reduction risk; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
